CD19 and lymphoma: A recent Phase 1 trial by Svoboda et al. using huCART19-IL18 (IL-18–armored, humanized CD19 CAR T) in 21 lymphoma patients relapsing after prior CD19 CAR T showed ORR 81% and CR 52% at 3 months, with durable remissions (median DOR 9.6 months).